Clinical Trial Update: Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies

View source ↗

Summary

This clinical trial update reports a special drug use observational study of omalizumab (Xolair) in adolescents aged 12 to 17 with seasonal allergic rhinitis wh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergic Rhinitis | Status: COMPLETED